Literature DB >> 2481225

Model of prostaglandin-regulated cyclic AMP metabolism in intact platelets: examination of time-dependent effects on adenylate cyclase and phosphodiesterase activities.

B Ashby1.   

Abstract

The kinetics of prostaglandin-regulated cyclic AMP formation by intact human platelets were studied in the presence and absence of phosphodiesterase inhibitors. In the case of iloprost, a chemically stable analogue of prostaglandin I2, the shape of the time course varied with prostaglandin concentration. In the presence of phosphodiesterase inhibitors, low concentrations of iloprost gave a linear rate of cyclic AMP formation. At higher concentrations of iloprost, the initial rate increased as a saturable function of prostaglandin concentration but the curves decayed with time to give new linear rates of cyclic AMP formation with a different prostaglandin concentration dependence from the initial rates. Time courses were simulated using KINSIM [Anal. Biochem. 130: 134-145 (1983)], a kinetic simulation program that employs numerical integration, over a wide range of iloprost concentration (3 nM to 30 microM) by use of a simple model involving rapid activation of adenylate cyclase, followed by slow reversible transition of adenylate cyclase to an inactive form (desensitization) through a distinct inhibitory receptor. The model requires that the affinity for prostaglandins of both the stimulatory and inhibitory receptors declines with prostaglandin concentration, which may be related to the existence of high and low affinity receptor forms depending on the activation state of the appropriate GTP-binding protein. The same two-receptor model can be used to describe cyclic AMP metabolism in the absence of phosphodiesterase inhibitors, giving rise to characteristic peak and plateau effects in the time courses. The putative inhibitory receptor has an apparent affinity for prostaglandin lower than the stimulatory receptor in the case of iloprost and a higher affinity than the stimulatory receptor in the case of prostaglandin E1. The contribution of phosphodiesterase activation to the time course of cyclic AMP formation through phosphorylation by cyclic AMP-dependent protein kinase was assessed. It was shown that phosphodiesterase activation must be rapid. A plausible and perhaps complete description of prostaglandin-regulated cyclic AMP metabolism in platelets is presented.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2481225

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

1.  Inhibition of human platelet adenylate cyclase activity by adrenaline, thrombin and collagen: analysis and reinterpretation of experimental data.

Authors:  A Juska; R W Farndale
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  Identification of a region of the C-terminal domain involved in short-term desensitization of the prostaglandin EP4 receptor.

Authors:  M Bastepe; B Ashby
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

3.  Prostaglandin-concentration-dependent desensitization of adenylate cyclase in human erythroleukaemia (HEL) cells is abolished by pertussis toxin and enhanced by induction by dimethyl sulphoxide.

Authors:  B Ashby; G O Almonor; E Wernick; M A Selak
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

Review 4.  Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease.

Authors:  Eitan A Friedman; Martin L Ogletree; Elias V Haddad; Olivier Boutaud
Journal:  Thromb Res       Date:  2015-05-28       Impact factor: 3.944

5.  Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.

Authors:  J E Merritt; T J Hallam; A M Brown; I Boyfield; D G Cooper; D M Hickey; A A Jaxa-Chamiec; A J Kaumann; M Keen; E Kelly
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

6.  Prevention by theophylline of beta-2-receptor down regulation in healthy subjects.

Authors:  M G Derks; R P Koopmans; E Oosterhoff; C J Van Boxtel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

7.  Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.

Authors:  Chao Fang; Evi Stavrou; Alec A Schmaier; Nadja Grobe; Mariana Morris; Andrew Chen; Marvin T Nieman; Gregory N Adams; Gretchen LaRusch; Yihua Zhou; Matthew L Bilodeau; Fakhri Mahdi; Mark Warnock; Alvin H Schmaier
Journal:  Blood       Date:  2013-02-05       Impact factor: 22.113

8.  Role of cyclic AMP in promoting the thromboresistance of human endothelial cells by enhancing thrombomodulin and decreasing tissue factor activities.

Authors:  G Archipoff; A Beretz; K Bartha; C Brisson; C de la Salle; C Froget-Léon; C Klein-Soyer; J P Cazenave
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

9.  Cloning and expression of a prostaglandin E receptor EP3 subtype from human erythroleukaemia cells.

Authors:  S P Kunapuli; G Fen Mao; M Bastepe; L Y Liu-Chen; S Li; P P Cheung; J K DeRiel; B Ashby
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

10.  Comparison of the effects of prostaglandins E2 and I2 on testicular nociceptor activities studied in vitro.

Authors:  K Mizumura; J Sato; T Kumazawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.